Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GV, Tencent and Gilead Sciences will exit the vaccine and infectious disease drug developer in an initial public offering sized at about $110m.

The $46m JGC Mirai Innovation Fund will invest in startups working on net-zero emission, green infrastructure, lifestyle and industry 4.0 technologies globally.

Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.

Novo Seeds co-led a $61.7m round for the oncology therapy developer with Ysios Capital, following a Novo Nordisk Foundation grant.

CAS Investment Management has returned for a $34m series A-plus round that was led by CDH Wealth Management.

Amadeus V Technology Fund has closed with $153m in funding, having already backed multiple spinouts.

Novo Seeds co-led a $61.7m round for the oncology therapy developer to help commercialise research originating at University of Copenhagen and Rigshospitalet.

The pain management platform developer has now raised at least $125m altogether, after pulling in series C funding from investors including Optum.

Rakuten took part in a $37m round for virtual kitchen operator Taster while Nano Dimension is buying M12-backed 3D microprinter developer NanoFabrica for up to $54.9m.